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Increasing Knowledge Flows by Linking Innovation and Health – the 
Case of SAAVI 
 
REBECCA HANLIN 
 
Abstract 
 
Biotechnology and genomic innovation are seen as increasingly important for 
achieving public health goals in Africa. In particular, vaccines based on advances in 
genomic technology are deemed vital in the fight against HIV/AIDS. Public-Private 
Partnerships (PPPs) provide a collaborative mechanism to ensure these vaccines are 
developed when the private sector lacks incentives to develop these products. These 
partnerships provide new mechanisms for transferring the knowledge required to 
ensure vaccine development occurs as quickly and efficiently as possible. One such 
vaccine partnership is the South African AIDS Vaccine Initiative (SAAVI). This has 
been successful in ensuring ‘value added’ (benefit gained by taking part) is created for 
those involved particularly in the area of intangible value added determinants of 
collaboration and knowledge capacity. This paper outlines the results of a case study 
of SAAVI and argues that it provides evidence of a need to strengthen our 
understanding of the linkage between wider conceptual ‘systems’ of innovation and 
health. In particular, it espouses the usefulness of ‘Systems of Innovation’ thinking as 
a means to ensure that more specific focus is placed on process outputs such as 
collaboration and knowledge capacity. This will ensure that necessary knowledge 
flow is transferred between those working in the vaccine project for more efficient 
and effective operations. The research also raises questions about the possibility of 
such case studies highlighting areas of attention that need addressing if greater linkage 
is to occur between innovation and health at a wider health research policy level. 
 
Genomic technologies, neglected diseases and PPPs 
 
The ‘genomics revolution’ has highlighted the potential of new medical technologies. 
The successful sequencing of the Human Genome has provided the groundwork for 
the production of applications and technologies that will “revolutionize research in 
life science and the practice of medicine”.
1
 The World Health Organisation’s 2002 
Genomics and World Health report emphasised the role of functional genomics 
including proteomics, transcriptomics, gene regulation and bioinformatics as creating 
new solutions to the world’s leading health problems such as communicable diseases 
and cancer. 
 
However, there is growing recognition of a “genomics divide”
2
 whereby developing 
countries are unable to harness or access the potential benefits of the ‘genomics 
revolution’. In particular it has been shown that 90% of the world’s disease burden 
receives less than 10% of global health research spending.
3
 This 10/90 gap has given 
rise to the term ‘neglected diseases’ to describe those diseases, particularly affecting 
developing countries, for which there is little investment to find solutions. Examples 
of such diseases are HIV/AIDS, TB, malaria, chagas and sleeping sickness. Thus 
there were only 13 new chemical entities (NCEs) developed related to tropical 
diseases out of a total of 1223 NCEs developed between 1976 and 1996.
4
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One of the reasons put forward to explain why there is so little investment into finding 
solutions to neglected diseases is an economic one. Certain health related research and 
development (R&D) is seen by the private sector – the traditional sector that 
undertakes R&D development
5
 – as too risky and expensive to warrant investment. 
This is particularly true of vaccines for neglected diseases, which although socially 
important, are deem by industry as unprofitable because the people affected by these 
diseases lack sufficient purchasing power. One such vaccine is that for HIV/AIDS. 
 
Finding a vaccine for HIV/AIDS is the best long-term solution for a disease that is 
now the leading cause of death for adults in the world.
6
 38 million people are infected 
with HIV worldwide, with AIDS claiming three million lives a year.
7
 The economic 
and social consequences of HIV/AIDS are also dramatic: it is estimated that South 
Africa’s GDP will fall by 17% by 2010 as a result of AIDS.
8
 These figures have led 
people to argue that the possible social return on investment in a vaccine will be 
greater than any investment return to private industry by approximately 10- to 20-
fold.
9
 
 
Growing recognition of the 10/90 gap, the lack of private sector investment and the 
devastating affect of HIV/AIDS have led to efforts to promote research into vaccines 
for the disease. In particular, Public Private Partnerships (PPPs) are being seen as 
innovative collaborative arrangements that provide the right balance of funding and 
research expertise to develop vaccines for these diseases.
10
 PPPs have been defined as 
a relationship between at least one private and one public sector player who share 
(although not necessarily equally) the risk and benefits involved in their activities.
11
 
While PPPs provide an economic incentive to collaborate they also provide social 
incentives to do so because the partners can achieve more together than they can 
individually,
12
 particularly as the partnership evolves and trust and commitment are 
strengthened.
13
 PPPs provide an economic incentive to collaborate by reducing 
economic risks to those involved and a social form of incentive to collaborate by 
creating a whole greater than the sum of the parts creating “win-win interactions” 
using mutually beneficial strategies.
14
 As such, PPPs are likely to provide a 
sustainable mechanism for the development and provision of vaccines for diseases 
such as HIV/AIDS for the developing world. 
 
Examples of such PPPs include the International AIDS Vaccine Initiative (IAVI), the 
South African AIDS Vaccine Initiative (SAAVI), the Medicines for Malaria Venture 
(MMV), the European Developing Countries Clinical Trial Partnership and the 
Foundation for Innovative New Diagnostics (FIND). These partnerships focus on 
bringing together public funds to finance product development activities by public 
and private sector research organisations and others aimed at producing (new) drugs, 
vaccines and diagnostics. Organisationally these partnerships function, using product 
development techniques perfected in the private sector, through a not-for-profit 
organisation that acts as a broker or integrator of knowledge and resources ensuring 
that these are accessible and delivered to the various partners.
15
 Most of these product 
development PPPs operate at an international level; however, SAAVI is an example 
of a product development partnership that is a national level initiative. As such, it is 
smaller in scale and its partners are more easily defined. 
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Using the case study of SAAVI, this paper argues that ‘win-win interactions’ can be 
further strengthened within PPPs placed at the intersection of innovation and health if 
they explicitly, or overtly, acknowledge the importance of the process factors of 
collaboration and knowledge capacity, as expressed by Systems of Innovation’ 
thinking. This is at odds with the dominant economic argument for the use of PPP 
mechanisms, which places an emphasis on output. PPPs are seen as the most efficient 
and effective means to ensure products are developed. In the case of SAAVI, the 
partnership – as will be explained below – measures its success by the speed and 
effort spent on working towards developing a successful candidate vaccine against 
HIV/AIDS. 
 
Systems of Innovation thinking, by contrast, considers the mechanisms by which 
outcomes are best achieved. In particular, this body of literature places an emphasis 
on the dynamics of interaction and learning involved in product innovation. 
Innovation systems approaches developed from the 1970s when questions where 
asked as to why different countries had different growth rates and whether this was 
related to research systems, with the concept of ‘innovation systems’ being coined by 
Lundvall in 1985.
16
 A system of innovation is “constituted by elements and 
relationships which interact in the production, diffusion and use of new, and 
economically useful, knowledge”.
17
 This approach is based on the assumption that 
innovation is a learning process
18
 taking an evolutionary economics perspective to 
economic growth and technological change which emphasises variety (the processes 
that influence innovative activity) and selection (the process of choice related to 
economic importance of different products).
19
 Selection is deemed to take place 
within the social environment with systemic interaction between actors,
20
 creating a 
system of innovation that is both social and dynamic.
21
 This interaction is reinforced 
by – and in turn reinforces – the place of learning within the process of innovation. 
Thus the two ‘tenets’ of systems of innovation relate to collaboration and knowledge 
capacity. 
 
Focusing on the process factors of collaboration and knowledge capacity brings 
together those involved in vaccine development but who traditionally have worked in 
separate areas. Acknowledging the role of these process factors would strengthen the 
vaccine development activities of a PPP such as SAAVI. This paper will also consider 
the possibility of extending the analysis to the wider area of health research policy. 
This is because taking process factors of collaboration and knowledge capacity as a 
starting point suggests the possibility of creating a more sustainable overarching 
learning system that transcends the traditional barriers between ‘innovation’ and 
‘health’ at policy level. 
 
The SAAVI case study 
 
Set up in 2000, SAAVI – a partnership between the South African government, a 
number of public sector research organisations and private sector and parastatal 
companies as financiers – aims to develop an effective and affordable HIV vaccine 
for South Africa and the surrounding region. SAAVI funds clinical development (but 
not, at the time of this study, clinical trials - although it did assist in the development 
of infrastructure and start-up activities at clinical trial sites) through a collaborative 
mechanism centrally coordinated by a directorate and with the expertise of a scientific 
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advisory board. SAAVI’s research activities are conducted by public research 
organisations mainly within South Africa. 
 
I conducted a case study of SAAVI in mid-2005. The study considered the extent to 
which value added, or benefit gained from taking part, had been created for members 
of the partnership. In particular the case study aimed to investigate whether process-
related intangible benefits such as organisational relations were created, and if they 
were deemed by partnership members as important for success (defined as ‘effective 
partnership working to ensure a vaccine was developed’). Previous studies on PPPs 
have focused on larger governance processes and the economic incentives to 
partnership; there has been little research that considers how process factors played 
out on the ground within a product development PPP. 
 
In May 2005, semi-structured interviews were conducted with members of the 
SAAVI directorate, the research groups involved in laboratory studies, clinical trials 
and ethical or socio-behavioural studies, and major funding agencies. Direct 
observation and document acquisition were also conducted and the trip had been 
preceded by a literature review. The data collected covered organisations’ partnership 
activities; why organisations became involved with SAAVI; and partnership progress 
and future. In particular, interviewees were asked about their organisation’s 
motivations for entering the partnership and the benefits gained from taking part. 
Interviewees were also asked how partnership success should be measured as a way to 
understand the importance placed on the benefits gained from taking part. 
 
 
Figure 1. Typology of value added in the SAAVI partnership 
 
 
 
 
 
It should be noted that the case study coincided with a period of change within 
SAAVI. It was in the midst of a management transition and several research grants 
were about to complete their funding cycle in August 2005. This had led to an 
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increase in tension and a major breakdown in communications between the directorate 
and the research groups as well as an (apparent) lack of coordination from the 
directorate during this transition. These issues may have influenced how interviewees 
answered some of the questions. 
 
The data collected showed that those involved in SAAVI had felt value added, or 
benefit gained from taking part. The benefits gained ranged from tangible financial 
returns to more intangibly defined benefits relating to collaboration and capacity 
building. A typology outlining this value added is outlined in Figure 1. 
 
The typology outlines the forms of value added most frequently cited by those 
interviewed. Collaboration and capacity building were deemed as equally important, 
less tangible forms of value added by those involved in SAAVI. However, 
collaboration received a higher importance because it was felt that it was no longer 
possible to work alone on projects and that such collaboration actually built capacity 
building opportunities. As interviewees explained: 
 
‘Well the global trend with research is if you work on your own is 
that you get far less done than if you work with others; and you have 
to leverage as much as possible…And what we were able to do was 
get far more done than predicted…In addition, the advantage for 
other researchers was that by collaborating they made themselves 
more powerful.’ 
Senior SAAVI directorate leader 
 
and 
 
“with partnership for planning the trials…the immunoassays… 
making the vaccines…we have managed to build capacity we didn’t 
have before.” 
Laboratory scientist 
 
Capacity building was therefore a second and subsequent value added for SAAVI 
members. The term ‘capacity building’ was used to refer to tangible activities such as 
staff training and also to more intangible building of knowledge capacity. 
Interviewees talked about “vast amounts of learning” and having had a “steep learning 
curve”. Although many organisations had been involved in vaccine related work 
before, few had been involved in HIV vaccine work. Working within the SAAVI 
partnership meant learning new knowledge not only related to HIV science but also 
knowledge around community education, HIV prevention, regulation, grant writing 
and working with others. This occurred at different levels of the partnership: in the 
laboratories, the clinical sites and within the SAAVI directorate. New knowledge had 
been gained through partnership activities relating to the process of vaccine 
production, ethical and legal issues and regulation by those previously uninvolved in 
such issues: 
 
“We have taken people from straight research through to being able 
to function in a GLP [Good Laboratory Practice] environment, to 
understand what is needed to get things through the regulatory 
council” 
Laboratory scientist 
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Value added through collaboration and capacity building was seen as a more 
important form of value added than credibility gained from taking part or financial 
return. A number of interviewees mentioned that the SAAVI partnership had provided 
useful sources of funding that would not necessarily have been available from other 
sectors. Others mentioned that it was sometimes useful “to have that SAAVI name 
behind you” because SAAVI is a “credit to the world”. However comments referring 
to these two areas of value added were not as numerous as comments relating to 
collaboration and capacity building. 
 
Despite the high ranking collaboration received as a value added, it was not deemed 
an important measure of success. The most important measure of success found 
during data analysis was related to the tangible creation of a vaccine. Successful 
creation of a vaccine was deemed the most important measure of success and as such 
the partnership members placed most emphasis on an outcome focus of the 
partnership over process orientated measures such as capacity building, good 
structure, communications and work competence. One of the reasons why an 
emphasis was placed on SAAVI’s mission of developing an HIV vaccine – on an 
outcome focus – is related to the way the partnership was created. Circumstances (the 
existence of some scientific capacity and the impact HIV/AIDS was having on South 
Africa) and an altruistic focus (local scientists felt they had the capacity to do 
something) resulted in SAAVI’s creation. The primary focus within SAAVI in its 
initial years on developing a vaccine had placed a great importance on activities 
related to the science of vaccinology, particularly preventative vaccines, at the 
expense of clinical trials and the ethical and socio-behavioural aspects of later-stage 
vaccine development and bringing a vaccine to market. Overwhelmingly people 
talked about the fact that “[e]veryone wants to see a vaccine” while “ultimately 
success will be measured by the degree of achievement of the primary mission of 
SAAVI”. Furthermore, the structure of the SAAVI partnership highlighted this divide 
by virtue of the fact that the clinical trial sites received less support relative to the 
work required
22
 while the socio-behavioural research group had only been set up in 
late 2004. 
 
Thus the measures of success highlighted by interviewees as those the partnership 
should be measured by were not the same as the factors they identified as being 
important value added or benefit gained by taking part. This was due to motivation for 
the partnership being centred on the need to combat the current HIV/AIDS epidemic 
in South Africa. The result has been an overwhelming focus on production of a 
product – a viable and effective HIV vaccine. Collaboration between scientists was 
deemed essential for this to occur but, together with knowledge capacity building, 
were seen as of secondary importance as a measure of success. 
 
Resonance with Systems of Innovation’s focus on collaboration and capacity 
 
Viewing the partnership through the lens of Systems of Innovation (SI) thinking may 
provide useful insights on ways forward for a partnership like SAAVI. Work in the 
area of SI places a strong emphasis on the process factors of collaboration and 
knowledge-related capacity building, which were the most important value added 
identified during the SAAVI case study, but were not seen as important measures of 
success. SI thinking is a holistic approach to innovation that places an emphasis on 
            Genomics, Society and Policy 
            2006, Vol.2, No.3, pp.37-48 
 
_____________  43 
 
Genomics, Society and Policy, Vol.2 No.3 (2006) ISSN: 1746-5354 
© ESRC Genomics Network. www.gspjournal.com 
improving the innovation environment to ensure more successful outcomes, 
suggesting that process factors about how a partnership works can be important 
success measures. 
 
SI theory was developed – as outlined at the beginning – around the two ‘tenets’ of 
collaboration and knowledge capacity. These are seen as a means to improve a firm’s 
ability to innovate. Collaborative arrangements, such as partnerships are seen as a 
means of managing and extending the knowledge base available.
23
 In particular 
collaborative arrangements are deemed essential to ensure the full exchange of 
information.
24
 Greater degrees of collaboration and interaction correlate with higher 
degrees of learning because competition is lower and there is more trust in the 
system.
25
 
 
Collaboration assists in the development and transfer of knowledge capacity. The 
ability of collaboration to transfer knowledge is determined by the extent to which it 
creates and is further reinforced by “absorptive capacity”. Absorptive capacity relates 
to a firm’s ability to recognise the value of knowledge, acquire, assimilate, and apply 
it.
26
 Absorptive capacity strengthens a firm’s ability to implement KM – the ability of 
a firm to create, codify, transfer and apply knowledge.
27
 Being within a partnership 
extends the range of knowledge available and increases the resources used in 
innovation thus improving a firm’s absorptive capacity.
28
 Improving absorptive 
capacity increases the level of learning that occurs and thus further builds absorptive 
capacity.
29
 
 
The emphasis SI thinking places on collaboration and capacity resonates with the 
activity of SAAVI and the emphasis SAAVI’s members placed on these process 
factors as important benefits gained from taking part in the partnership. Analysis of 
the interviews suggests that the SAAVI partnership, through its members’ interactions 
with each other and the outside world, has the ability to create, diffuse and use 
knowledge to build absorptive or knowledge-based capacity. SAAVI places an 
implicit emphasis on collaborative activities and knowledge capacity-building 
activities in its operations while outwardly focusing on progress towards achievement 
of its objective to develop an HIV vaccine. These activities are seen as an important 
value added or benefit gained from taking part but as yet are not seen as an important 
measure of success. SI theory however places these process factors centre stage and 
imperative for successful innovation: 
 
‘economic creativity is actually about the quality of “technological 
linkages” and “knowledge flows” amongst and between economic 
agents. Where the interactions are dynamic and progressive great 
innovative strides are often made. Conversely where systemic 
components are compartmentalised and isolated from each other, 
the result is often that relevant bodies are not at all productive.’
30
 
 
Focusing more explicitly on the process factors of collaboration and knowledge 
capacity building suggests a means by which SAAVI could work more effectively 
towards its goal of developing an HIV vaccine. Emphasising collaboration and 
making collaborative activities more explicit as a goal provides an opportunity for 
further knowledge exchange between those involved in vaccine development work. 
Most obviously it provides greater opportunity for building of stronger scientific 
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research capacity through increased skills and knowledge at the level of the laboratory 
and trial sites. However, the SAAVI partnership brings together these traditional 
actors in innovation involved in the ‘science’ or R&D of possible HIV candidate 
vaccines with those who are more traditionally involved in healthcare activities and 
community education activities. As such, an emphasis on collaborative activity and 
greater knowledge exchange between these groups would also occur. This provides an 
opportunity to build more understanding and linkages between those working here as 
community educators and healthcare workers with the scientific staff in the 
laboratories. This is important as traditional healthcare activities are often viewed as 
separate from clinical research activities but these are in fact intricately connected.
31
 
Partnerships like SAAVI offer a new mechanism for transferring knowledge required 
to ensure vaccine development occurs as quickly and effectively as possible. Focusing 
on collaboration and in particular, the knowledge exchange possibilities that this type 
of partnership can create, provides a means of creating an overarching learning 
system from which more integrative HIV vaccine development activity within SAAVI 
would take place.  
 
Discussion – linking innovation and health 
 
It may be possible to extend this analysis around overarching learning systems in the 
context of health research policy where there has also been a traditional separation 
between science and technology innovation and healthcare activities. Science and 
technology policy has not specifically emphasised health related activities in the past 
because such policy has been generated from a narrow concept of economic growth.
32
 
At the same time, health policy has traditionally only considered healthcare activities. 
(The World Health Report of 2000 recognised that the concept of health systems in 
the past concerned the provision and investment in healthcare only.) Thus activities 
involving science and technology innovation or research have tended not to engage 
directly with more traditional healthcare related provision activities. 
 
There is growing recognition of the need to consider science and technology 
innovation and healthcare activities at the same time. There are calls that the science 
and technology, particularly biotechnology related R&D, capacity of developing 
countries is important if they are to achieve the Millennium Development Goals
33
 and 
that these are important inputs to a health system. Emphasis is also being placed on 
strengthening ‘health research’ – “the generation of new knowledge using the 
scientific method to identify and deal with health problems”
34
 – in developing 
countries and the need to close the 10/90 health research gap. Such research refers not 
only to the generation of scientific knowledge on new products and processes (R&D) 
but also knowledge relating to their application and utilisation
35
 so that more informed 
policy and practice can take place. 
 
Health policy analysts have developed the concept of a ‘health research system’
36
 as a 
conceptual tool around which policy makers in developing countries can work to 
strengthen health research activities. This system consists of the “people, institutions 
and activities whose primary purpose is to generate and apply high-quality knowledge 
that can be used to promote, restore and/or maintain the health status of populations”
37
 
and lies at the intersection between the health system and the wider research system. 
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The idea of a health research system highlights the way those involved in the 
healthcare system and those conducting traditional research activities can generate 
useable and relevant health research knowledge. This goes some way towards the idea 
of creating an overarching learning system but without the emphasis placed on the 
collaborative activity that such a system requires. A concept related to health research 
strengthening that does encompass this is that of the ‘health innovation system’ which 
has been developed from SI thinking. A health innovation system is the network of 
institutions whose “interactions and activities generate and/or use scientific 
knowledge and produce (as well as apply) technologies to solve specific disease 
problems”.
38
 
 
This concept places an emphasis on process factors of collaboration and knowledge 
capacity at the policy level when considering health research activities. This may 
provide a means of creating a more sustainable overarching learning system that 
would transcend the traditional barriers between ‘innovation’ and ‘health’ at the 
policy level and provide a way to reduce the gap between seemingly discrete 
‘systems’ of science and technology innovation and health. 
 
Conclusion 
 
The SAAVI case study highlights the undervalued nature that the process factors of 
collaboration and knowledge capacity have been given within the partnership. While 
seen as important benefits gained from taking part in the SAAVI partnership by 
members, they were not seen as important measures of success. This is despite the 
fact that both were deemed important for member’s activities within the partnership 
and, therefore, for the process of the partnership itself. As such, the members within 
the SAAVI partnership appeared to put an implicit as opposed to an explicit or overt 
emphasis on these process factors. SI thinking recognises the value of these process 
factors. It places an emphasis on collaboration and capacity as being central to 
advancing innovative activities through partnership. Focusing explicitly on these 
process factors may provide a means of creating an overarching learning system. 
Within this system it is possible to work towards objectives much more effectively as 
knowledge flow is increased within a partnership between those working in vaccine 
development activities in areas of scientific R&D and those involved in healthcare 
work. 
 
The case study also raises questions about the possibility of such studies highlighting 
areas that need addressing if greater linkage is to occur between innovation and health 
at a health research policy level. The SAAVI case study showed the existence of a 
linkage between innovation and health. Embracing this linkage within the wider 
research policy sphere is necessary because scientific capacity is not a means to an 
end but an important end in itself within the health system. There is a need for the 
policy system to work within a wider systemic approach that includes not only health 
but also science and technology. An emphasis on collaboration and absorptive 
capacity within the health research policy environment would move beyond 
references to the ‘health system,’ which is seen simply in terms of outcomes with 
vaccines as a product input that assists service provision. Such a perspective would 
instead acknowledge the importance of output (knowledge capacity) for the building 
of a wider conceptualised systemic framework to health research policy. This does not 
            Genomics, Society and Policy 
            2006, Vol.2, No.3, pp.37-48 
 
_____________  46 
 
Genomics, Society and Policy, Vol.2 No.3 (2006) ISSN: 1746-5354 
© ESRC Genomics Network. www.gspjournal.com 
mean championing output process factors such as knowledge or absorptive capacity 
over outcomes, but instead stresses their inter-relationship. This is because an 
emphasis is placed on the role of absorptive capacity (understanding the value and use 
of knowledge) in linking science and technology innovation or research activities with 
healthcare activities. 
 
It would be wrong – after only one small case study – to advocate the use of either the 
conceptual frameworks ‘health innovation systems’ or the ‘health research system’ as 
being the way forward in ensuring a more connected health research policy arena. 
This case study was, at most, an institutional level study but it does suggest that more 
research needs to be done in this area. This is a young and as yet rather unexplored 
area of research, and conducting a small case study of SAAVI raises more questions 
than it answers and opens a number of avenues for further research. For example, it 
highlights a need to consider what information should be transferred within a vaccine 
partnership in order to be successful and that there are possible lessons to be learnt for 
the wider area of health research policy. 
 
Furthermore, the case study has introduced an issue that potentially could have 
significant impact on the way policy is formulated. More systemic frameworks such 
as ‘health innovation systems’ and the ‘health research system’ are being supported 
but little work has yet been conducted to consider how such frameworks should be 
moved forward. This paper highlights the possibility of using institutional level 
analysis of health research activities that spans the innovation and health divide as one 
possible way forward. The paper also highlights the potential use of systems of 
innovation thinking as a framework within which to work. 
 
The aim of this paper has been to highlight that studying activities at an institutional 
level can provide important insights for the wider policy arena to take into account. 
The case of HIV/AIDS vaccine development in South Africa provides one example of 
where an institutional level study of a research partnership highlights the interaction 
between what are usually – particularly within the wider policy arena – considered as 
separate areas of activity, namely (science and technology research) innovation and 
health(care provision). Focusing on the process factors of collaboration and 
knowledge capacity may provide a means of creating a more sustainable overarching 
learning system that would reduce the gap between seemingly discrete ‘systems’ of 
science and technology innovation and health within the partnership. This paper 
suggests that focusing on these may also provide a means to move towards not only 
more integrated vaccine development work, but also to more integrated systemic 
health research policy. 
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